Literature DB >> 15247129

Lysophospholipids are potential biomarkers of ovarian cancer.

Rebecca Sutphen1, Yan Xu, George D Wilbanks, James Fiorica, Edward C Grendys, James P LaPolla, Hector Arango, Mitchell S Hoffman, Martin Martino, Katie Wakeley, David Griffin, Rafael W Blanco, Alan B Cantor, Yi-jin Xiao, Jeffrey P Krischer.   

Abstract

OBJECTIVE: To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting.
METHOD: Plasma samples were collected from ovarian cancer patients and healthy control women in Hillsborough and Pinellas counties, Florida, and processed at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute (Moffitt). Case patients with epithelial ovarian cancer (n = 117) and healthy control subjects (n = 27) participated in the study. Blinded LPL analysis, including 23 individual LPL species, was performed at the Cleveland Clinic Foundation using an electrospray ionization mass spectrometry-based method. LPL levels were transmitted to Moffitt, where clinical data were reviewed and statistical analyses were performed.
RESULTS: There were statistically significant differences between preoperative case samples (n = 45) and control samples (n = 27) in the mean levels of total LPA, total lysophosphatidylinositol (LPI), sphingosine-1-phosphate (S1P), and individual LPA species as well as the combination of several LPL species. The combination of 16:0-LPA and 20:4-LPA yielded the best discrimination between preoperative case samples and control samples, with 93.1% correct classification, 91.1% sensitivity, and 96.3% specificity. In 22 cases with both preoperative and postoperative samples, the postoperative levels of several LPL, including S1P, total LPA, and lysophosphatidylcholine (LPC) levels and some individual species of LPA and LPC, were significantly different from preoperative levels.
CONCLUSION: LPA, LPI, LPC, and S1P appear useful as diagnostic and prognostic biomarkers of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247129

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  108 in total

Review 1.  The human plasma lipidome.

Authors:  Oswald Quehenberger; Edward A Dennis
Journal:  N Engl J Med       Date:  2011-11-10       Impact factor: 91.245

2.  Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.

Authors:  Feng Su; Kathy R Kozak; Satoshi Imaizumi; Feng Gao; Malaika W Amneus; Victor Grijalva; Carey Ng; Alan Wagner; Greg Hough; Gina Farias-Eisner; G M Anantharamaiah; Brian J Van Lenten; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 3.  Mass spectrometry based cellular phosphoinositides profiling and phospholipid analysis: a brief review.

Authors:  Youngjun Kim; Selina Rahman Shanta; Li-Hua Zhou; Kwang Pyo Kim
Journal:  Exp Mol Med       Date:  2010-01-31       Impact factor: 8.718

4.  The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray.

Authors:  Elena Deliu; Margaret Sperow; Linda Console-Bram; Rhonda L Carter; Douglas G Tilley; Daniel J Kalamarides; Lynn G Kirby; G Cristina Brailoiu; Eugen Brailoiu; Khalid Benamar; Mary E Abood
Journal:  Mol Pharmacol       Date:  2015-05-13       Impact factor: 4.436

5.  A Robust Lipidomics Workflow for Mammalian Cells, Plasma, and Tissue Using Liquid-Chromatography High-Resolution Tandem Mass Spectrometry.

Authors:  Candice Z Ulmer; Rainey E Patterson; Jeremy P Koelmel; Timothy J Garrett; Richard A Yost
Journal:  Methods Mol Biol       Date:  2017

Review 6.  Lysophosphatidic acid (LPA) signaling in vertebrate reproduction.

Authors:  Xiaoqin Ye; Jerold Chun
Journal:  Trends Endocrinol Metab       Date:  2010-01       Impact factor: 12.015

7.  An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples.

Authors:  Zhenwen Zhao; Yan Xu
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

Review 8.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 9.  Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.

Authors:  C Evangelisti; C Evangelisti; F Buontempo; A Lonetti; E Orsini; F Chiarini; J T Barata; S Pyne; N J Pyne; A M Martelli
Journal:  Leukemia       Date:  2016-07-27       Impact factor: 11.528

10.  Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines.

Authors:  Wei Guan; Manshui Zhou; Christina Y Hampton; Benedict B Benigno; L Deette Walker; Alexander Gray; John F McDonald; Facundo M Fernández
Journal:  BMC Bioinformatics       Date:  2009-08-22       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.